Published in BMJ Open on July 25, 2016
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (2015) 9.65
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol (1997) 9.01
A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc (2009) 5.81
GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Interpretation of random effects meta-analyses. BMJ (2011) 4.32
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol (2010) 4.10
GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol (2011) 3.54
GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44
Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology (2012) 3.35
Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med (2014) 3.30
GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02
How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med (2005) 2.95
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol (2011) 2.69
Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol (2012) 2.58
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods (2012) 2.57
Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health (2008) 1.92
Conceptual and technical challenges in network meta-analysis. Ann Intern Med (2013) 1.92
Demystifying trial networks and network meta-analysis. BMJ (2013) 1.87
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (2014) 1.82
Evaluation of inconsistency in networks of interventions. Int J Epidemiol (2013) 1.72
Indirect comparisons: a review of reporting and methodological quality. PLoS One (2010) 1.65
Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics (1989) 1.63
Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics (2009) 1.58
Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health (2014) 1.43
Management of patent ductus arteriosus in preterm infants--where do we stand? Congenit Heart Dis (2013) 1.41
Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr (2005) 1.34
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed (2010) 1.24
Abnormal cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatrics (1982) 1.13
Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. J Pediatr (1979) 1.12
Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth. Pediatrics (2006) 1.12
Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol (2014) 1.11
Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr (1984) 1.10
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol (2012) 1.07
Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res (1991) 1.04
Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One (2013) 1.02
Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr (1991) 1.00
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev (2013) 0.96
Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. CMAJ (2006) 0.95
Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. Pediatrics (2012) 0.93
The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis (2010) 0.88
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants. Cochrane Database Syst Rev (2015) 0.82
Placebo-controlled trials: when are they needed? Schizophr Res (1999) 0.79